Evaluation of the relevance of serum level of interleukin-8 in chronic lymphocytic leukemia

Abstract: BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting the elderly. It is characterized by monoclonal B-cell proliferation expressing CD5 and CD23. Interleukin-8 (IL-8) has been found to induce the proliferation of malignant cells and make them resistant to apoptosis. Thus, IL-8 could be implicated in disease progression. OBJECTIVE: The objective of the study was To determine the clinical significance of serum IL-8 levels in CLL patients and to evaluate its potential as a biomarker for disease progression. MATERIALS AND METHODS: A cross-sectional study was conducted on 30 CLL patients and 30 normal individuals (control). Participants were recruited from October 2024 and continuing until August 2025 at The National Center of Hematology/Mustansiriyah University. Patients’ demographics were collected using a special form. Blood samples were collected and analyzed for IL-8 levels using ELISA in addition to complete blood count. RESULTS: The mean serum IL-8 level for CLL patients was 28.83 ± 12.68 pg/mL, which is higher than that of the control group 10.20 ± 1.008 pg/mL, with no statistical significance ( P = 0.1483). It was concluded that a statistically significant difference in IL-8 levels existed across all stages of CLL ( P = 0.0193). The highest median level was 16.28 pg/mL in Stage A, whereas the median levels in Stages B and C were 7.476 pg/mL and 7.608 pg/mL, respectively. The receiver operating characteristic curve showed that IL-8 powerful in distinguishing between Stage A and C, with a sensitivity of 81.82%, and a specificity of 72.73% at a cutoff of 10.07 pg/mL. IL-8 does not show a significant correlation with other variables. CONCLUSION: As an autocrine growth and apoptosis resistance factor, higher level of IL-8 among CLL patients may be related to the disease persistence, with higher levels among earlier stages of CLL in comparison to later stages, which may be related to immune system exhaustion. Thus, it could be useful in monitoring disease status.

Authors

Institutions

Publication Details

Journal
Iraqi Journal of Hematology
Published
2026-03-14
DOI
https://doi.org/10.4103/ijh.ijh_161_25
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of the relevance of serum level of interleukin-8 in chronic lymphocytic leukemia

Huda Ibraheem Abd Al-Lateef, Alaadin Sahham Naji, Wurood Alaa Hasan, Dina Wael Abed et al.
Iraqi Journal of Hematology
Chronic Lymphocytic Leukemia Research
article

Evaluation of the relevance of serum level of interleukin-8 in chronic lymphocytic leukemia

Huda Ibraheem Abd Al-Lateef, Alaadin Sahham Naji, Wurood Alaa Hasan, Dina Wael Abed, Shahla’a Fadhil Sabir
article en

Abstract

Abstract: BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting the elderly. It is characterized by monoclonal B-cell proliferation expressing CD5 and CD23. Interleukin-8 (IL-8) has been found to induce the proliferation of malignant cells and make them resistant to apoptosis. Thus, IL-8 could be implicated in disease progression. OBJECTIVE: The objective of the study was To determine the clinical significance of serum IL-8 levels in CLL patients and to evaluate its potential as a biomarker for disease progression. MATERIALS AND METHODS: A cross-sectional study was conducted on 30 CLL patients and 30 normal individuals (control). Participants were recruited from October 2024 and continuing until August 2025 at The National Center of Hematology/Mustansiriyah University. Patients’ demographics were collected using a special form. Blood samples were collected and analyzed for IL-8 levels using ELISA in addition to complete blood count. RESULTS: The mean serum IL-8 level for CLL patients was 28.83 ± 12.68 pg/mL, which is higher than that of the control group 10.20 ± 1.008 pg/mL, with no statistical significance ( P = 0.1483). It was concluded that a statistically significant difference in IL-8 levels existed across all stages of CLL ( P = 0.0193). The highest median level was 16.28 pg/mL in Stage A, whereas the median levels in Stages B and C were 7.476 pg/mL and 7.608 pg/mL, respectively. The receiver operating characteristic curve showed that IL-8 powerful in distinguishing between Stage A and C, with a sensitivity of 81.82%, and a specificity of 72.73% at a cutoff of 10.07 pg/mL. IL-8 does not show a significant correlation with other variables. CONCLUSION: As an autocrine growth and apoptosis resistance factor, higher level of IL-8 among CLL patients may be related to the disease persistence, with higher levels among earlier stages of CLL in comparison to later stages, which may be related to immune system exhaustion. Thus, it could be useful in monitoring disease status.

Iraqi Journal of Hematology
University of Baghdad (IQ), Mustansiriyah University (IQ), Baghdad Medical City (IQ)
Good health and well-being
Openalex Percentile: Top 23%
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.